Lapatinib (free base), Inhibitor

Lapatinib (free base)

Cat. Num. AAA385512

• Purity: >98%
• Synonyms: Lapatinib (free base); inhibitor

• Purity/Purification: >98%
• Form/Format: Powder
• Concentration: 0.1 mM: 17.21 mL (1 mg); 86.04 mL (5 mg); 172.09mL (10 mg); 0.5 mM: 3.44 mL (1 mg); 17.21 mL (5 mg); 34.42 mL (10 mg); 1 mM: 1.72 mL (1 mg); 8.6 mL (5 mg); 17.21 mL (10 mg); 5 mM: 0.34 mL (1 mg); 1.72 mL (5 mg); 3.44 mL (10 mg) (varies by lot)

• CAS Number: 231277-92-2
• Formula: C29H26ClFN4O4S
• SMILES: CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl
• In Vivo Solvent: 15% Captisol
• Solubility (DMSO): 100 mg/mL (172.09 mM)
• Solubility (Ethanol): <1 mg/mL (<1 mM)
• Solubility (in vivo): 30 mg/mL
• Solubility (Water): <1 mg/mL (<1 mM)
• Availability: We cannot ship this item to Switzerland, Italy, Germany, France and Austria.
• Preparation and Storage: at -20 degree C 3 years Powder

Chemical Structure

Related Product Information for Lapatinib (free base), inhibitor

Lapatinib is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway.

References

Momeny M, .et al. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells, Cell Oncol (Dordr), 2019, Apr 25 PMID: 31025257
Tzeng SF, .et al. O-Glycosylation-mediated signaling circuit drives metastatic castration-resistant prostate cancer, FASEB J, 2018, Jun 15:fj201800687 PMID: 29906246
Fujita KI, .et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
Yuki Kawasaki, .et al. Feedback control of ErbB2 via ERK-mediated phosphorylation of a conserved threonine in the juxtamembrane domain, Sci Rep, 2016, 6: 31502 PMID: 27531070
Tetsuya Saita, .et al. Preparation of Antibodies and Development of an Enzyme-Linked Immunosorbent Assay for the Tyrosine Kinase Inhibitors Lapatinib and Nilotinib., Biol Pharm Bull. , 2015, 38(10):1652-7 PMID: 26424026